Abstract: The present invention relates to a composition containing as its main component proanthocyanidin oligomer to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight, which is obtained by heating plant materials containing proanthocyanidin polymer or extract thereof with a substance having a phloroglucinol ring structure or resorcinol ring structure in an acidic aqueous solution, production method thereof, and uses of the composition in health products and pharmaceutical products. According to the invention, proanthocyanidin oligomer having physiological activity, to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight to such a level that the oligomer can be absorbed into living body, which has been conventionally difficult to obtain at high yield from plant raw materials, can be produced efficiently and easily.

Abstract: It provides the effective power conversion control technique which it can control which it made use of a characteristic (nature) of each A/D converter in. It comprises the third control part including the third operating circuit it inputs signal from third A/D converter inputting the detecting signal which is different from the detecting signal which is the same as the detecting signal or the detecting signal and above third A/D converter, and to generate the third operating signal, and the above actuating management circuit manages the actuating of an above first control part and the second above control part and the third above control part.

Abstract: A highly accurate control is achieved in such a way that a timing value is generated from a differential control amount calculation result and a filter calculation result at iteration intervals not exceeding the iteration intervals of the filter calculation and then the timing set value of a driving signal generation circuit is updated by this timing value. A device for controlling a power conversion circuit comprises an AD conversion circuit (22), a driving timing value generation circuit (23), and a driving signal generation circuit (24). The driving timing value generation circuit (23) includes a control amount calculation circuit (231) and a digital-digital addition circuit (232). The digital-digital addition circuit (232) generates a driving timing value for a switch of a power conversion circuit. The driving signal generation circuit (24) receives the driving timing value and generates a driving signal for the switch (11) of the power conversion circuit (1).

Abstract: The frequency decision device determines frequency of the measured rectangular signal by simple and easy means. The frequency decision device inputs the measured rectangular signal that frequency (or period) changes dynamically. It generates a rectangular reference signal of predetermined on width ? synchronizing to the edge based on a positive going edge of this measured rectangle signal. And it watches the order of measured rectangle signal and falling edges of the rectangular reference signal. When this sequential order reversed, it detects that length of the ON time of ON time of the measured rectangle signal and the measured rectangular signal reversed.

Abstract: Disclosed are a device and a method for comparing a detected frequency signal (first frequency signal) and a second frequency signal which is obtained by delaying the detected frequency, to determine whether the frequency transitioned to a predetermined area on high frequency side or reached a predetermined value on the upward direction side. The frequency detection device (1) comprises: a delayed signal output circuit (11) that outputs a second frequency signal (F2) obtained by delaying the first frequency signal (F1), which has a frequency that changes over time, by a set period (?i); and a determination circuit (12), which inputs the first frequency signal (F1) and the second frequency signal (F2), determines whether or not the cycle of the first frequency signal (F1) is included in the cycle of the second frequency signal (F2) and/or whether or not the cycle of the second frequency signal (F2) is included in the cycle of the first frequency signal (F1), and outputs a determination signal.

Abstract: In DC/DC converter circuit, the peak value of the reactor current is found based on output voltage and an input voltage, thereby, the operation with the predetermined electric current mode is thereby enabled. The AC/DC converter circuit is run with a predetermined current mode, the power factor improvement is accomplished. The first control part 211 inputs a detected value of output voltage Eo, and a turn-off timing predicted value of switch Tr of the DC/DC converter 1 is calculated. The first control part 211 sends the calculation result to the switch drive signal generate part 213. The second control part 212 inputs the detected value of the output voltage and the input voltage, and it receives the turn-off timing predicted value from the first control part 211.

Abstract: The invention provides a method of treating chronic pain by administering an effective amount of a low-molecular weight compound that inhibits the enzyme activity of autotaxin to a subject in need thereof, thereby treating chronic pain in the subject. The chronic pain preferably is fibromyalgia, chronic fatigue syndrome, or hypersensitivity colitis.

Abstract: The present invention provides a non-human mammal deficient in the expression of prothymosin ? gene in the striatum and a screening method for a prophylactic/therapeutic drug for Huntington's disease and the like, which uses the animal.

Abstract: The present invention identifies a compound which binds to the PAH1 domain of mSin3B that specifically binds to neural restrictive silencer factor NRSF, and uses the compound as a prophylactic and/or a therapeutic for diseases associated with abnormal expression of neural restrictive silencer factor NRSF/REST or abnormal expression of genes targeted by NRSF/REST, such as Huntington's disease, medulloblastoma and neuropathic pain. The present invention provides a pharmaceutical composition comprising a substance capable of binding to the PAH1 domain of mSin3B, e.g.

Abstract: This invention provides a nano composite porous electrode material that has high charge-discharge behavior and charge or discharge capacity and a manufacturing method thereof. It also provides a lithium-ion secondary battery using this nano composite porous electrode material. The nano composite porous electrode material according to this invention has a porous structure such that nano-size pores are three-dimensionally connected with each other wherein walls of the pores thereof are composed of olivine type LiMnPO4 and carbon, a specific surface area Sa is 55 m2g?1<Sa<248 m2g?1, an amount of contained carbon Cc is 15.5 wt %<Cc<28 wt % and a diameter of crystallite is less than 39 nm. This enables a high charge-discharge capacity and a fast charge or discharge behavior to be obtained.

Abstract: The invention provides an antigen or drug delivery complex containing a complex of an antigen or drug and a cationic molecule, and an anionic molecule encapsulating the same. The antigen or drug delivery complex can be used as a main component of a drug delivery system that delivers various antigens and drugs to a particular cell or organ.

Abstract: The invention provides a method of ameliorating a blood-brain barrier disorder, as well as a method of treating a disease accompanied by a blood-brain barrier disorder and a method of treating a cerebral ischemic disease, by administering a prothymosin ?, or a protein or polypeptide possessing the same function as the prothymosin ?. The invention also provides polypeptides useful in the context of the aforesaid methods.

Abstract: Provided is a process for producing an optically active compound represented by Formula (3): (wherein R1 is an alkyl group, an alkynyl group, an alkenyl group, an aliphatic heterocyclic group, a cycloalkyl group, an aryl group, an aralkyl group, or an aromatic heterocyclic group, and any hydrogen atom of R1 may be replaced with a substituent; R2 is a hydrogen atom or a group which is not reactive in the reaction below; and * represents a chiral center) or a salt thereof by subjecting a compound represented by Formula (1): (wherein R1 and R2 have the same meanings as defined in Formula (3)) to a ring closure reaction in the presence of a chiral ligand having 1 or more coordination sites, a Lewis acid represented by Formula (2): MmZn??(2) (wherein M is a metal ion, Z is a counter anion of M, and m and n are integers of 1 to 4), and a sulfonyl halide having an optionally substituted alkyl or phenyl group.

Abstract: The invention provides a method of detecting uracil. The method comprises reacting uracil with a compound represented by the formula (I) in the presence of an oxidant and a base to produce a fluorescent compound represented by the formula (II).

Abstract: The present invention provides a prophylactic or therapeutic agent for HAM, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention also provides an agent for improving a HAM-associated movement disorder, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Provided is a vibration control device, which enables the vibrations of a vibrating body, such as a rotary machine, to automatically be suppressed, without installing a vibration detection sensor on the vibration control device or vibrating body, and without controlling the rotational speed or phase of the vibration control device. The vibration control device (1), which is installed on a vibrating body (2) and controls the vibrations of the vibrating body (2), comprises a rotating shaft (11), a mass body (12) that is fixed to the rotating shaft (11), and an activation apparatus (13) that adds the power of a rotational motion, which is centered on the rotating shaft (11), to the mass body (12).

Abstract: Provided is a therapeutic or prophylactic agent for generalized pain syndrome, for which no cause and therapies have been established. A therapeutic or prophylactic agent for generalized pain syndrome containing an LPA1 antagonist or autotaxin-inhibiting substance as an active ingredient. The pharmaceutical is preferably administered to the central nervous system. The generalized pain syndrome is preferably fibromyalgia, chronic fatigue syndrome or hypersensitivity colitis.

Abstract: The present invention provides a metal complex containing a cation represented by [(MII)2(MI)2(LC)2(LB)4]2+ [in the aforementioned formula, MII is PtII or PdII, MI is H+, AuI, AgI, CuI, HgI, TlI or PbI, and LC and LB are ligands]. The metal complex of the present invention is useful as a light emitting material of an organic EL device.

Abstract: The present invention provides a non-human mammal deficient in the expression of prothymosin ? gene in the striatum and a screening method for a prophylactic/therapeutic drug for Huntington's disease and the like, which uses the animal.

Abstract: The present invention provides a useful examination method and diagnostic reagent, which are capable of diagnosing acute lung injury in clear distinction from chronic progressive interstitial pneumonia. Specifically, the present invention provides a method of determining whether or not a test subject is affected with acute lung injury, which comprises quantifying heat shock protein 47 in a biological sample derived from the test subject.